NCT04391803终止不适用
EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)
Medtronic Neurovascular Clinical Affairs7 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2022年5月6日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 25
- 试验地点
- 7
- 主要终点
- Incidence of complete angiographic occlusion without significant stenosis, and no rebleeding or retreatment of the target aneurysm
研究概览
简要总结
The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
详细描述
The ELEVATE study is a prospective, multi-center, single-arm trial of the Pipeline™ Shield Device for the treatment of adults with acutely ruptured intracranial aneurysms. The primary objective of the ELEVATE study is to assess the safety and effectiveness of treatment with the Pipeline™ Shield Device of acutely ruptured intracranial aneurysms that are not amenable for clipping and coiling.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has a previously untreated, wide neck, side-wall, intradural aneurysm that is deemed unfavorable for both surgical clipping and endovascular coiling, as confirmed on DSA.
- •Subject has a ruptured intracranial aneurysm with vessel diameter suitable for treatment with the study device.
- •Subject is ≥ 22 and ≤ 80 years of age.
- •Subject has an acutely ruptured aneurysm with Hunt and Hess Scale 1, 2 or
- •Subject or subject's Legally Authorized Representative (LAR) has provided written informed consent.
排除标准
- •Subject's vessel characteristics preclude safe endovascular access to the aneurysm to treat with the Pipeline™ Shield Device.
- •Subject has aneurysm vessel characteristics that would preclude the device from fully conforming to the parent vessel to reduce any risk of embolic complications, retreatment, or device movement.
- •Subject has true bifurcation or aneurysms with vessels that cannot be separated from the fundus with placement of the study device.
- •Subject with intraparenchymal hemorrhage.
- •Subject is unable to undergo nasogastric/orogastric tube placement prior to device placement.
- •Subject has a pre-morbid mRS >
- •Subject requires treatment of another aneurysm (with another treatment modality) within the affected territory of the target aneurysm.
- •Subject has a target ruptured aneurysm that is thought to be mycotic, including those caused by left atrial myxoma, or subject has an active systemic bacterial infection.
- •Subject with a requirement for continuous anti-coagulation.
- •Subject has a malignant brain tumor or vascular malformation (e.g. arteriovenous malformation).
- •Subject's target ruptured aneurysm has not been determined by the treating physician to be the source of SAH.
- •Subject with known allergy to platinum or cobalt chromium alloy (including the major elements platinum, cobalt, chromium, nickel or molybdenum).
- •Subject has a known hypersensitivity to ticagrelor or aspirin.
- •Subject is unable to undergo DSA or DSA is determined unsuitable by the treating physician.
- •Subject has a serious or life-threatening comorbidity that could confound study results.
- •Subject is at high risk of noncompliance per treating physician due to reasons including but not limited to a history of substance abuse.
- •Subject is unable to complete scheduled follow-up assessments due to comorbidities, geographical limitations, or a life expectancy of less than 24 months.
- •Subject is pregnant, or breastfeeding at the time of admission or plans to become pregnant during their participation in the study.
- •Subject is participating in another clinical study at the time of enrollment.
- •Presumed septic embolus, or suspicion of microbial superinfection.
- •Subject with a known COVID-19 viral infection, confirmed by testing.
- •Subject in whom a pre-existing stent is in place in the parent artery at target aneurysm location.
研究组 & 干预措施
Pipeline™ Flex Embolization Device with Shield Technology™
Experimental
This is a prospective, single-arm study in which subjects have consented and deployment of the Pipeline™ Flex Embolization Device with Shield Technology™ is attempted.
干预措施: Pipeline™ Flex Embolization Device with Shield Technology™ (Device)
结局指标
主要结局
Incidence of complete angiographic occlusion without significant stenosis, and no rebleeding or retreatment of the target aneurysm
时间窗: at 365-day
Occlusion is measured by the Raymond Roy Scale. Significant stenosis is classified as ≤ 50%.
Incidence of neurological death or disabling stroke post-procedure.
时间窗: at 365-day
Disabling stroke is defined as any post-procedural ischemic or hemorrhagic event that results in poor functional outcome (i.e. mRS ≥ 3 points) assessed at 90 days post stroke event.
次要结局
- Incidence of parent artery thrombosis(through 365-day post procedure)
- Incidence of peri-/post-procedural serious adverse events related to the device, procedure or antiplatelet therapy(through 180-day and 365-day post procedure)
- Incidence of any ipsilateral stroke post-procedure after 30 days(through 180-day and 365-day post procedure)
- Incidence of in-construct stenosis > 50%(through 365-day post procedure)
- Incidence of rebleed of target aneurysm(through 180-day and 365-day post procedure)
- Incidence of retreatment(through 180-day and 365-day post procedure)
- Incidence of neurological death or disabling stroke(through 365-day post procedure)
- Incidence of complete angiographic occlusion without significant stenosis (≤ 50%), and no rebleeding or retreatment of the target aneurysm(through 365-day post procedure)
- Incidence of neurological hemorrhagic serious adverse events(through 180-day and 365-day post procedure)
- Incidence of ipsilateral major stroke or neurological death post-procedure after 30 days(through 180-day and 365-day post procedure)
- Good clinical outcome (modified Rankin Scale (mRS) 0-2)(at 30-day, 180-day and 365-day post procedure)
- Pipeline™ Flex Device Deployment Success Rate(Day 0 During Procedure)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
不适用
Pipeline™ Flex Embolization Device With Shield Technology™ Clinical StudyAneurysmNCT02390037Medtronic Neurovascular Clinical Affairs50
已完成
不适用
Novel Endovascular Access Trial (NEAT)Chronic Kidney DiseaseNCT02036671C. R. Bard80
终止
不适用
Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)Intracranial AneurysmNCT03873714Medtronic Neurovascular Clinical Affairs14
已完成
不适用
Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDyIntracranial AneurysmNCT02719522Medtronic Neurovascular Clinical Affairs205
已完成
不适用
Pipeline for Uncoilable or Failed AneurysmsIntracranial AneurysmNCT00777088Medtronic Neurovascular Clinical Affairs108